Solara Active Pharma Sciences (NSE:SOLARAPP1) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Solara Active Pharma Sciences EBITDA Margin % Related Terms
Solara Active Pharma Sciences EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solara Active Pharma Sciences EBITDA Margin % Chart
NSE:SOLARAPP1 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Solara Active Pharma Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solara Active Pharma Sciences EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Solara Active Pharma Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Solara Active Pharma Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a EBITDA Margin % of 16.32% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Solara Active Pharma Sciences and its competitors. This is 19% above median its historical median of 13.66. According to the industry distribution chart, Solara Active Pharma Sciences ranks #450 out of 954 companies in the Drug Manufacturers industry, placing it in the top 47.2%.
Is Solara Active Pharma Sciences' EBITDA Margin % too high?
Solara Active Pharma Sciences' current EBITDA Margin % of 16.32% is 19% above median its 10-year median of 13.66. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Solara Active Pharma Sciences' value of 16.32% is 30.4% above this industry median. Based on the distribution chart, Solara Active Pharma Sciences ranks #450 out of 954 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Solara Active Pharma Sciences has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Solara Active Pharma Sciences' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Solara Active Pharma Sciences ranks #450 out of 954 companies for EBITDA Margin %. This puts Solara Active Pharma Sciences in the upper half of its industry. The industry median EBITDA Margin % is 12.52. Solara Active Pharma Sciences' value of 16.32% is 30.4% above this benchmark. While the company's 10-year median is 13.66 vs. the industry median of 12.52, Solara Active Pharma Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solara Active Pharma Sciences's current EBITDA Margin % of 16.32% is 30.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Solara Active Pharma Sciences and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solara Active Pharma Sciences's current EBITDA Margin % is 16.32%, which is 19% above median its own 10-year median of 13.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solara Active Pharma Sciences stock overvalued right now?
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a current EBITDA Margin % of 16.32%. The stock's GF Value™ is ₹263.62, compared to a current price of ₹267.45 — trading 1.5% above its estimated fair value. The current EBITDA Margin % is 16.32%, which is 19% above median its 10-year median of 13.66 and 30.4% above the Drug Manufacturers industry median of 12.52. Solara Active Pharma Sciences' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Solara Active Pharma Sciences (NSE:SOLARAPP1), the current EBITDA Margin % is 16.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solara Active Pharma Sciences (NSE:SOLARAPP1) Overvalued in 2026?
Based on GuruFocus' analysis, Solara Active Pharma Sciences stock appears to be overvalued.
The current stock price of ₹267.45 is trading 1.5% above its estimated GF Value™ of ₹263.62.
Key valuation signals for NSE:SOLARAPP1:
EBITDA Margin %: 16.32% (19% above median its 10-year median of 13.66)
GF Value™: ₹263.62 vs. price of ₹267.45 (1.5% above fair value)
Industry Position: 30.4% above the Drug Manufacturers median (#450 of 954)
No single metric tells the full story. See the NSE:SOLARAPP1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Solara Active Pharma Sciences Business Description
Solara Active Pharma Sciences Ltd is engaged in the Active Pharmaceutical Ingredients (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinoid, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant, and others. It also offers contract services, including contract development and manufacturing, and analytical services. Geographically, the company generates all of its revenue from India.
67GF Score
Get the complete analysis for NSE:SOLARAPP1
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOLARAPP1 has been successfully added to your 
